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INTRODUCTION
Along with the efficacy and safety of drugs, the 
interaction of drugs with each other and with oth-
er accompanying substances, such as components of 
food, mineral water, other drinks etc. is no less im-
portant. Medicines containing polyvalent metal cat-
ions, such as antacids, iron supplements, de-nol, etc. 
constitute a significant group of drugs for medical 
use. Common recommendations for use are present-
ABSTRACT
INTRODUCTION: Along with the efficacy and safety of drugs, the interaction of drugs with each other and 
with other accompanying substances is important, too. There are no data about the interaction or influence 
of antacids and other drugs with polyvalent cations on the metronidazole bioavailability. The purpose of 
this research was the studying of the metronidazole release kinetics from the tablets in an environment that 
simulates stomach conditions with the addition of metal salts, which are part of the widespread drugs. The 
research was conducted to assess the impact of possible interactions between the active substance and poly-
valent metal cations on their bioavailability and efficacy.
MATERIAL AND METHODS: Metronidazole tablets were chosen as research object. 0.1 N HCl solution 
with addition of metal salts was chosen as medium dissolution. The “PharmaTest-DT70” Device with bas-
ket, the “Evolution 60S” Spectrophotometer as well as the “AB 204 S/A METTLER TOLEDO” analytical bal-
ances were used in the study.
RESULTS: Research of chemical interaction between metronidazole and metal salts, which are part of the 
widespread drugs, in the experiment “in vitro” was carried out. Metal salts don’t influence the metronida-
zole release from the tablets, as evidenced by dissolution profiles and similarity factors for each of the cases.
CONCLUSIONS: The chemical interactions between the chosen medicines were not observed in the “in vi-
tro” experiment. Thus, separate intake of metronidazole with other drugs, containing metal cations, is im-
portant for further research in the “in vivo” experiment.
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ed in the guidelines such as separate intake of medi-
cines with metal salts with other drugs because of the 
possibility of insoluble complexes formation. But pa-
tients do not always follow the common rules of tak-
ing drugs, referring to the need of immediate elim-
ination of symptoms of heartburn and pain in the 
stomach (19).
With regard to some drugs such as pantopra-
zole (16), ketoprofen, amoxicillin (18) it was noted 
that antacids in therapeutic concentrations do not 
influence the bioavailability whereas the interaction 
during simultaneous application has not been estab-
lished (16). Thus, the general recommendations in 
the given case need not be taken into account.
There are no data on the problem of interaction 
or influence of antacids and other drugs with polyva-
lent cations on the bioavailability as far as some other 
drugs such as metronidazole are concerned (8, 17). In 
this case doctors and pharmacists advise being guid-
ed by the general recommendations for using drugs 
containing metal cations. But these recommenda-
tions are not always confirmed experimentally.
As for metronidazole and a number of drugs, 
used for the treatment of gastrointestinal patholo-
gy, obtaining reliable data on the interaction of drugs 
with polyvalent cations is important since the prob-
ability of their combined use due to a number of dif-
ferent causes is very high. Therefore, in our opinion, 
research in this direction is important for practical 
medicine and pharmacy.
As a result of previous works (3-5,7,9-10) the 
probability of interaction between metronidazole 
and some metal salts, which are part of different 
pharmacological drugs groups, was established. It 
should be noted that research of interaction was car-
ried out without complying with specific conditions 
of the reaction medium that simulates stomach con-
ditions and reactants were used in molar ratios ac-
cording to valence metal cations.
The aim of this study was to investigate the ki-
netics of metronidazole release from the tablets in 
an environment that simulates stomach conditions, 
(pH 1.2; t° (37±0.5) °C) with the addition of metal 
salts, which are part of the common drugs contain-
ing metal cations, to assess the impact of possible in-
teractions between the active substance and polyva-
lent metal cations upon the bioavailability and phar-
macological efficacy of both drugs.
MATERIAL AND METHODS
The object of study is metronidazole tablets 
“Metronidazole-Zdorovya” with the content of the 
active substance constituting 250 mg (manufac-
tured by ”Zdorovya” Pharmaceutical company Ltd., 
Kharkiv, Ukraine, Series: 40415). 
The metal salts such as anhydrous calcium 
chloride, magnesium sulphate heptahydrate, alu-
minium sulphate oktadekahydrate, iron (II) sulphate 
heptahydrate, iron (III) chloride hexahydrate, bis-
muth subnitrate were of analytical purity grade and 
used without further purification. They were added 
to the dissolution medium as components of phar-
maceuticals of inorganic nature.
The working standard sample (WSS) of metro-
nidazole (manufactured by Hubei Hongyuan Phar-
maceutical Co.,  Ltd, China, Series: 20130541) was 
used to prepare the metronidazole reference solution.
The assaying of active ingredient was conduct-
ed by spectrophotometric method in the ultraviolet 
and visible spectrum by the standard method.
The “PharmaTest-DT70” Device with basket 
(Germany), the “Evolution 60S” Spectrophotometer 
(USA), the “AB 204 S/A METTLER TOLEDO” ana-
lytical balances (Poland) as well as class A measuring 
vessel and reagents that conform to the State Phar-
macopoeia of Ukraine (SPhU) (12-14) which are har-
monized with the European ones (1) were used in the 
study. 
The release kinetics was studied according to 
the SPhU monographs, Supplement 2 “2.9.3. Test 
“Dissolution” for solid dosage forms”, “5.N.2. Re-
search of bioavailability and bioequivalence of gener-
ic medicines” (13), the guidelines “Drugs. Investiga-
tion of bioequivalence” (6), the monograph USP 26 
Test “Dissolution” (18), the SPhU monograph, Sup-
plement 4 “Metronidazole tablets” (14).
Statistical analysis of the results was performed 
according to the SPhU monograph, Supplement 1 
“5.3.N. Statistical analysis of the results of chemical 
experiments” (12). Microsoft Office Excel was used 
for calculations and statistical analysis of obtained 
data.
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To simulate the environment of the stomach, 0.1 
M solution of hydrochloric acid of pH 1.2 was used. 
The calculated amounts of salts were dissolved in it 
separately. The amounts of metal salts were calculat-
ed in terms of quantitative content of metal cations in 
the medium therapeutic doses of appropriate drugs.
Conditions of the “Dissolution” test were as fol-
lows: the dissolution medium volume was 1000 mL, 
the environment temperature was (37±0.5) °C; the 
basket’s rotational speed – 100 rev/min. The overall 
time of the study constituted 95 min. The samples 
were taken every 5 minutes, after the point of 15 min 
– every 15 min., after the point of 45 min – every 10 
min. Samples were taken manually with the Mohr 
pipette with a capacity of 10.0 mL of the middle area 
between the surface of the dissolution medium and 
the top of the basket, no closer than 1 cm from the 
surface vessel. The volume of elongated aliquot was 
not compensated by pure solvent, which was taken 
into account in the calculation formula. Investigat-
ed samples were filtered through the filter “Blue Rib-
bon” immediately after extraction.
Test solution. 2.0 ml of investigated sample fil-
trate was adjusted to the volume of 25.0 ml with 0.1 
M hydrochloric acid solution.
Reference solution. 
The amount of metronidazole WSS about 
0.0250 g is dissolved with 0.1 M hydrochloric acid so-
lution and adjusted to the mark of 100.0 ml with the 
same solvent. The aliquot of 2.0 ml of the resulting 
solution is taken and placed in the 25.0 ml volumetric 
flask and adjusted to the mark with the same solvent.
Compensation solution. 
To measure the absorbance of the researched 
samples, the compensation solution was prepared in 
the following way: 2.0 ml of dissolution medium was 
placed in a 25.0 ml volumetric flask and the volume 
adjusted to the mark with 0.1 M hydrochloric acid 
solution.
For measuring the reference solution as com-
pensation solution, 0.1 M hydrochloric acid solution 
was used.
The measurement of the absorbance of the test 
solutions and the reference solution wa carried out 
on a spectrophotometer at 277 nm wavelength in a 
ditch with a layer thickness of 10 mm.
The assaying of metronidazole in the taken 
samples was calculated using the formula 
where: 
 ❖ A – absorbance of the test solution;
 ❖ A
0
 – absorbance of the reference solution;
 ❖ m
 
– study drug sample weight amount;
 ❖ m
0
 – standard sample weight amount;




 – volume of taken aliquot.  
Rationing: at least 80% of the nominal metroni-
dazole content.
The similarity of dissolution profiles was estab-




number of control points;
 ❖ R
(t)
 – average of the active substance amount, 
which turned into solution at each control point 
for reference preparation (as a percentage of the 
value specified on the label);
 ❖ T
(t)
 – average of the active substance amount, 
which turned into solution at each control point 
for test preparation (as a percentage of the value 
specified on the label) (6,11,13).
Also, for each of the control points the relative 
standard deviation of the mean result  was calculat-
ed, which must satisfy the following criteria: for the 
first control point it must be less than 20%, and for 
the rest of control points it must be less than 10% 
(6,11,13).
RESULTS AND DISCUSSION
According to the literature metronidazole is ab-
sorbed well and rapidly taken orally, with the bio-
availability constituting approximately 100%; the 
concentration maximum is achieved in 1-2 hours de-
pending on the dose – from 6 to 40 mg/l. It binds 
to plasma proteins up to 20%. Metronidazole pene-
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trates the tissues and body fluids, passes through the 
histohematogenous barriers, provides therapeutic 
concentrations in cerebrospinal fluid and brain tis-
sue, and penetrates into breast milk, actively secret-
ed with saliva and gastric juice. The half-life is 6-10 
hours. About 30-60% of metronidazole is biotrans-
formed in the liver. Up to 60-80% of metronidazole 
is excreted mainly by renal excretion, the unchanged 
metronidazole amounts to about 20%; from 6% to 
15% of it is excreted with the bile and feces (7, 5,19).
Thus, according to the literature (7,15,19) and 
experimental data for biopharmaceutical solubility 
and degree of penetration according to the Biophar-
maceutics Classification System (BCS) (2,6,13,20) 
metronidazole can be attributed to the first class of 
solubility, which confirms the possibility of in vitro 
bioequivalence studies.
Dissolution profiles are shown in Fig. 1. Re-
search results of the kinetics of metronidazole release 
from the tablets in dissolution medium, which con-
tains dissolved metal salts in concentration, which 
were calculated from the average therapeutic appli-
cable concentration, are presented in Table 1. Besides 
the concentration values of dissolved medical sub-
stance, these similarities factors and relative stan-
dard deviations for each of investigated samples are 
also presented.
As can be seen in Figure 1, the dissolution pro-
files are very similar to each other, deviation within 
the allowed norms, nature of charts are not signifi-
cantly different between themselves and the control 
experiment. Disintegration of tablets and the disso-
lution of the metronidazole active substance in all 
cases in these conditions have been observed with-
in five minutes from the start of the research, as evi-
denced by the dissolution profiles shown in Figure 1. 
Fig. 1. Dissolution profiles of metronidazole in dissolution 


































5 100.44 102.03 101.41 100.06 104.24 98.70 101.31
10 98.92 100.37 98.99 99.46 103.78 97.49 100.12
15 98.37 99.19 99.06 99.08 102.24 96.64 99.50
30 97.87 99.18 98.67 97.15 101.20 95.26 97.17
45 96.34 99.29 97.15 95.84 99.50 93.94 95.34
55 96.04 97.58 95.49 95.44 98.20 92.88 93.56
65 94.10 94.47 93.86 93.85 97.60 91.90 92.62
75 93.28 94.66 94.20 93.02 96.26 92.41 91.27
85 92.59 94.10 91.76 91.85 94.81 90.48 90.21





- 92.70 98.35 98.63 84.01 90.43 92.96
1.06 1.79 0.53 0.70 1.01 1.11 0.84
Table 1. Results of in vitro research into release kinetics of metronidazole from tablets in the mediums with the addition 
of metal salts
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According to the regulatory documents 
(6,13,18), as the research was carried out regarding 
the reference preparation, the confirmation of equiv-
alence relative to it, for all of the samples similarity 
factors f
2
 were calculated, which should be ≥50. In the 
case of bioequivalence studies of generic drugs rela-
tive to the original preparations, if the concentration 
of the active ingredient is more than 85% for 15 min-
utes, the similarity factors need not be taken into ac-
count (6,13). However, in the context of this study, we 
decided to calculate these indicators, as the concept 
of this experiment is different from the described 
documented procedures for determining drugs bio-
equivalence. As a result of the calculations, similar-
ity factors for five conducted studies were more than 
90%, only in the case of the dissolution medium with 
the addition of Fe (II) salts, the figure was 84%, but it 
also satisfies the requirements.
As a result of the statistical processing of the ob-
tained data (12) it was found that they satisfied the 
given requirements (6,13) and constitute less than 2% 
for each of the studies.
Thus, the obtained data shows that the chem-
ical interaction of metronidazole with metal salts, 
which are part of antacid drugs as well as drugs for 
the iron deficiency treatment, and some other prep-
arations containing metal cations, has no significant 
effect on the bioavailability of metronidazole in the 
“in vitro” experiment. The separate intake of metro-
nidazole with other drugs, containing metal cations, 
is important for further research in the “in vivo” 
experiment.
CONCLUSIONS
1. In the average therapeutic concentrations the 
chemical interaction between the metal salts, 
which are part of antacid and other drugs of 
inorganic nature, and metronidazole did not 
have any impact on the therapeutic concen-
tration of the latter, and may have no signifi-
cant impact on the bioavailability of metroni-
dazole in the “in vitro” experiment.
2. Similarity factors of dissolution profiles of 
metronidazole tablets in various mediums 
are ≥90%, in the case study of solubility in the 
medium with Fe2+ salt, the figure is 84% (dis-
solution profiles are considered similar if the 
similarity factor is f
2
≥50%) (6,13).
3. The value of relative standard deviation also 
conforms with the given criteria and is no 
more than 2% for each of the samples. 
4. The obtained results confirm the importance 
further research of interaction of metronida-
zole with the antacids and other metal salts 
containing drugs in the “in vivo” experiment.
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